Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × efatutazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Neoplasms 4 Carcinoma, Non-Small-Cell Lung 3 Thyroid Carcinoma, Anaplastic 2 Respiratory Tract Neoplasms 2 Colorectal Neoplasms 2 Thyroid Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma 1 Liposarcoma 1 Advanced Non-small Cell Lung Cancer (NSCLC) 1 Advanced Cancer 1

Interventions

Cyclophosphamide 405 Rituximab 362 Etoposide 205 Vincristine 194 Filgrastim 183 Doxorubicin 183 Prednisone 158 Cytarabine 145 Radiotherapy 144 fludarabine phosphate 130 Melphalan 121 Methotrexate 120 Peripheral Blood Stem Cell Transplantation 115 fludarabine 106 Busulfan 90 Dexamethasone 84 Carmustine 69 Granulocyte Colony-Stimulating Factor 64 Tacrolimus 63 Mycophenolic Acid 61 Gemcitabine 61 Whole-Body Irradiation 59 Bendamustine Hydrochloride 58 Antilymphocyte Serum 57 Lenalidomide 55 Cyclosporine 55 Ifosfamide 54 Bortezomib 52 sargramostim 43 Methylprednisolone 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01504490 2017-02-14

Phase I Study of CS-7017 and Bexarotene

Georgetown University

Phase 1 Terminated

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡